<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00266409</url>
  </required_header>
  <id_info>
    <org_study_id>SP0851</org_study_id>
    <nct_id>NCT00266409</nct_id>
  </id_info>
  <brief_title>Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder</brief_title>
  <official_title>A Multicenter, Randomized, Open-label, Parallel Design Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <brief_summary>
    <textblock>
      An 8-week, open-label trial in 848 subjects at 212 sites to compare time to response in
      symptoms of anxiety in subjects treated with Niravam™ and a newly prescribed Selective
      Serotonin Reuptake Inhibitor (SSRI)or Serotonin and Norepinephrine Reuptake Inhibitor (SNRI)
      to that in subjects treated with a newly prescribed SSRI/SNRI alone. Subjects must be at
      least 18 years of age and positive for Generalized Anxiety Disorder (GAD)or Panic Disorder.
      Subjects will be randomized to receive concomitant Niravam™ and an SSRI/SNRI or an SSRI/SNRI
      alone during the study. Most symptom evaluations will be done using an automated phone
      interview system. There are 4 clinic visits.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Percent of Participants Showing a Response in the Symptoms of Anxiety (Decrease in Total Hamilton Anxiety (HAM-A) -Score of &gt;=50%) in the Intent-to-treat Population (Kaplan-Meier-estimates)</measure>
    <time_frame>10 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Thus total possible score is 56. Kaplan-Meier-analysis was performed and Kaplan-Meier estimates (cumulative percent of subjects responding) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Percent of Participants Showing a Response in the Symptoms of Anxiety (Decrease in Total Hamilton Anxiety (HAM-A) -Score of &gt;=50%) in the Per Protocol Population (Kaplan-Meier-estimates)</measure>
    <time_frame>10 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Total possible score is 56. Kaplan-Meier-analysis was performed and Kaplan-Meier estimates (cumulative percent of subjects responding) are presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total HAM-A Score After 1 Week</measure>
    <time_frame>Baseline and 1 week</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total HAM-A Score After 2 Weeks</measure>
    <time_frame>Baseline and 2 Weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total HAM-A Score After 3 Weeks</measure>
    <time_frame>Baseline and 3 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total HAM-A Score After 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total HAM-A Score After 5 Weeks</measure>
    <time_frame>Baseline and 5 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total HAM-A Score After 6 Weeks</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total HAM-A Score After 7 Weeks</measure>
    <time_frame>Baseline and 7 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total HAM-A Score After 8 Weeks</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total HAM-A Score at Endpoint During the 8 Week Treatment Period</measure>
    <time_frame>Baseline and at endpoint during the 8 week treatment period</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56. Endpoint is last observed value during the 8 week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 1 Week</measure>
    <time_frame>1 week</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 2 Weeks</measure>
    <time_frame>2 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 3 Weeks</measure>
    <time_frame>3 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 4 Weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 5 Weeks</measure>
    <time_frame>5 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 7 Weeks</measure>
    <time_frame>7 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 8 Weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) at Endpoint During the 8 Week Treatment Period</measure>
    <time_frame>at endpoint during the 8 week treatment period</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Endpoint is last observed value during the 8 week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Severity of Illness From Baseline Using the Clinical Global Impression Improvement (CGI-I) Score After 2 Weeks</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>The Clinical Global Impression Improvement (CGI-I) scale is a 7 point ordinal scale that assesses how the patient's illness has improved ranging from 'very much improved' to 'very much worse'(see definition of categories in results table).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Severity of Illness From Baseline Using the Clinical Global Impression - Improvement (CGI-I) Score After 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The Clinical Global Impression Improvement (CGI-I) scale is a 7 point ordinal scale that assesses how the patient's illness has improved ranging from 'very much improved' to 'very much worse'(see definition of categories in results table).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Severity of Illness From Baseline Using the Clinical Global Impression - Improvement (CGI-I) Score After 8 Weeks</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>The Clinical Global Impression Improvement (CGI-I) scale is a 7 point ordinal scale that assesses how the patient's illness has improved ranging from 'very much improved' to 'very much worse'(see definition of categories in results table).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Severity of Illness From Baseline Using the Clinical Global Impression - Improvement (CGI-I) Score at Endpoint During the 8 Week Treatment Period</measure>
    <time_frame>Baseline and at endpoint during the 8 week treatment period</time_frame>
    <description>The Clinical Global Impression Improvement (CGI-I) scale is a 7 point ordinal scale that assesses how the patient's illness has improved ranging from 'very much improved' to 'very much worse'(see definition of categories in results table). Endpoint is last observed value during the 8 week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 1 Week</measure>
    <time_frame>1 week</time_frame>
    <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 2 Weeks</measure>
    <time_frame>2 weeks</time_frame>
    <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 3 Weeks</measure>
    <time_frame>3 weeks</time_frame>
    <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 4 Weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 5 Weeks</measure>
    <time_frame>5 weeks</time_frame>
    <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 7 Weeks</measure>
    <time_frame>7 weeks</time_frame>
    <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 8 Weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score at Endpoint During the 8 Week Treatment Period</measure>
    <time_frame>at endpoint during the 8 week treatment period</time_frame>
    <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables). Endpoint is last observed value during the 8 week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-insomnia Subscore After 1 Week</measure>
    <time_frame>Baseline and 1 week</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-insomnia Subscore After 2 Weeks</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-insomnia Subscore After 3 Weeks</measure>
    <time_frame>Baseline and 3 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-insomnia Subscore After 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-insomnia Subscore After 5 Weeks</measure>
    <time_frame>Baseline and 5 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-insomnia Subscore After 6 Weeks</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-insomnia Subscore After 7 Weeks</measure>
    <time_frame>Baseline and 7 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-insomnia Subscore After 8 Weeks</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-insomnia Subscore at Endpoint During the 8 Week Treatment Period</measure>
    <time_frame>Baseline and at endpoint during the 8 week treatment period</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4. Endpoint is last observed value during the 8 week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-psychic Factors Subscore After 1 Week</measure>
    <time_frame>Baseline and 1 week</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-psychic Factors Subscore After 2 Weeks</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-psychic Factors Subscore After 3 Weeks</measure>
    <time_frame>Baseline and 3 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-psychic Factors Subscore After 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-psychic Factors Subscore After 5 Weeks</measure>
    <time_frame>Baseline and 5 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-psychic Factors Subscore After 6 Weeks</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-psychic Factors Subscore After 7 Weeks</measure>
    <time_frame>Baseline and 7 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-psychic Factors Subscore After 8 Weeks</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-psychic Factors Subscore at Endpoint During the 8 Week Treatment Period</measure>
    <time_frame>Baseline and at endpoint during the 8 week treatment period</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4. Endpoint is last observed value during the 8 week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-somatic Subscore After 1 Week</measure>
    <time_frame>Baseline and 1 week</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-somatic Subscore After 2 Weeks</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-somatic Subscore After 3 Weeks</measure>
    <time_frame>Baseline and 3 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-somatic Subscore After 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-somatic Subscore After 5 Weeks</measure>
    <time_frame>Baseline and 5 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-somatic Subscore After 6 Weeks</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-somatic Subscore After 7 Weeks</measure>
    <time_frame>Baseline and 7 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-somatic Subscore After 8 Weeks</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A-somatic Subscore at Endpoint During the 8 Week Treatment Period</measure>
    <time_frame>Baseline and at endpoint during the 8 week treatment period</time_frame>
    <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4. Endpoint is last observed value during the 8 week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 1 Week</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 2 Weeks</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 3 Weeks</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 4 Weeks</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 5 Weeks</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 7 Weeks</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 8 Weeks</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) at Endpoint During the 8 Week Treatment Period</measure>
    <time_frame>at endpoint during the 8 week treatment period</time_frame>
    <description>Endpoint is last observed value during the 8 week treatment period.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">418</enrollment>
  <condition>Generalized Anxiety Disorder</condition>
  <condition>Panic Disorder</condition>
  <arm_group>
    <arm_group_label>Panic: Niravam+SSRI/SNRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panic: SSRI/SNRI alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GAD: Niravam+SSRI/SNRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Generalized Anxiety Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GAD: SSRI/SNRI alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niravam</intervention_name>
    <arm_group_label>Panic: Niravam+SSRI/SNRI</arm_group_label>
    <arm_group_label>GAD: Niravam+SSRI/SNRI</arm_group_label>
    <other_name>Alprazolam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSRI/SNRI</intervention_name>
    <description>Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor</description>
    <arm_group_label>Panic: Niravam+SSRI/SNRI</arm_group_label>
    <arm_group_label>Panic: SSRI/SNRI alone</arm_group_label>
    <arm_group_label>GAD: Niravam+SSRI/SNRI</arm_group_label>
    <arm_group_label>GAD: SSRI/SNRI alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be at least 18 years of age.

          -  Diagnosed by the Investigator with primary Generalized Anxiety Disorder (GAD) and/or
             primary Panic Disorder with or without agoraphobia, either primary episode or
             recurrence, and is positive for GAD or Panic Disorder by the MHS (Mental Health
             Screener)).

          -  Receiving a new prescription for all SSRI or SNRI as indicated for GAD or Panic
             Disorder with or without agoraphobia. Definition of a new prescription in case of a
             recurrence in symptoms is no prescription or refill of prescription of SSRI or SNRI
             for the past 6 months.

          -  Subject is informed and given ample time and opportunity to think about his/her
             participation and has given his/her written informed consent.

        Exclusion Criteria:

          -  Presence of medical condition or presence of schizophrenia, bipolar disorder, alcohol
             abuse/dependence or any other primary major psychiatric disorder that, in the opinion
             of the Investigator, would jeopardize the subject or compromise the subject's ability
             to participate in the trial.

          -  Is a current suicide risk in the opinion of the Investigator.

          -  Has initiated cognitive therapy within two months of Study Day 1.

          -  Does not speak English or does not hear well enough to be able to perform the Hamilton
             Anxiety (HAM-A) Rating Scale and Mental Health Screener (MHS) by Interactive Voice
             Response System (IVRS).

          -  Has taken a benzodiazepine within the past 30 days.

          -  History of hypersensitivity or allergic response to any of the components of SSRIs,
             SNRIs, benzodiazepines, or related drugs.

          -  If a female of child-bearing potential, is pregnant, nursing, or not using appropriate
             birth control methods.

          -  Presence of contraindications to the SSRI or SNRI to be prescribed per the specific
             package insert.

          -  Presence of acute narrow angle glaucoma or taking ketoconazole or itraconazole,which
             are contraindications to Niravam per the package insert.

          -  History of phenylketonuria (PKU).

          -  Participation in a previous clinical trial within 30 days prior to Study Day 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Schwarz</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <results_reference>
    <citation>Katzelnick DJ, Saidi J, Vanelli MR, Jefferson JW, Harper JM, McCrary KE. Time to response in panic disorder in a naturalistic setting: combination therapy with alprazolam orally disintegrating tablets and serotonin reuptake inhibitors compared to serotonin reuptake inhibitors alone. Psychiatry (Edgmont). 2006 Dec;3(12):39-49.</citation>
    <PMID>20877555</PMID>
  </results_reference>
  <results_reference>
    <citation>Rapaport MH, Skarky SB, Katzelnick DJ, Dewester JN, Harper JM, McCrary KE. Time to response in generalized anxiety disorder in a naturalistic setting: combination therapy with alprazolam orally disintegrating tablets and serotonin reuptake inhibitors compared to serotonin reuptake inhibitors alone. Psychiatry (Edgmont). 2006 Dec;3(12):50-9.</citation>
    <PMID>20877556</PMID>
  </results_reference>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2005</study_first_submitted>
  <study_first_submitted_qc>December 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2005</study_first_posted>
  <results_first_submitted>May 5, 2009</results_first_submitted>
  <results_first_submitted_qc>August 25, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 2, 2009</results_first_posted>
  <last_update_submitted>October 17, 2014</last_update_submitted>
  <last_update_submitted_qc>October 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Panic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Serotonin and Noradrenaline Reuptake Inhibitors</mesh_term>
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants Flow shows 418 subjects that have been enrolled and randomized. The safety population consists of 414 subjects that received at least one dose of SSRI/SNRI and/or Niravam.</recruitment_details>
      <pre_assignment_details>Baseline Characteristics are only available for the Intent-to-treat population (subjects who received one dose of SSRI/SNRI and/or Niravam and have an assessment beyond the Baseline assessment)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Panic: Niravam+SSRI/SNRI</title>
          <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
        </group>
        <group group_id="P2">
          <title>Panic: SSRI/SNRI Alone</title>
          <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
        </group>
        <group group_id="P3">
          <title>GAD : Niravam+SSRI/SNRI</title>
          <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
        </group>
        <group group_id="P4">
          <title>GAD: SSRI/SNRI Alone</title>
          <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="138"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Panic: Niravam+SSRI/SNRI</title>
          <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
        </group>
        <group group_id="B2">
          <title>Panic: SSRI/SNRI Alone</title>
          <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
        </group>
        <group group_id="B3">
          <title>GAD : Niravam+SSRI/SNRI</title>
          <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
        </group>
        <group group_id="B4">
          <title>GAD: SSRI/SNRI Alone</title>
          <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="125"/>
            <count group_id="B2" value="120"/>
            <count group_id="B3" value="67"/>
            <count group_id="B4" value="62"/>
            <count group_id="B5" value="374"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.1" spread="12.24"/>
                    <measurement group_id="B2" value="38.1" spread="12.55"/>
                    <measurement group_id="B3" value="40.1" spread="12.64"/>
                    <measurement group_id="B4" value="43.6" spread="12.20"/>
                    <measurement group_id="B5" value="40" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Percent of Participants Showing a Response in the Symptoms of Anxiety (Decrease in Total Hamilton Anxiety (HAM-A) -Score of &gt;=50%) in the Intent-to-treat Population (Kaplan-Meier-estimates)</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Thus total possible score is 56. Kaplan-Meier-analysis was performed and Kaplan-Meier estimates (cumulative percent of subjects responding) are presented.</description>
        <time_frame>10 weeks</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Percent of Participants Showing a Response in the Symptoms of Anxiety (Decrease in Total Hamilton Anxiety (HAM-A) -Score of &gt;=50%) in the Intent-to-treat Population (Kaplan-Meier-estimates)</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Thus total possible score is 56. Kaplan-Meier-analysis was performed and Kaplan-Meier estimates (cumulative percent of subjects responding) are presented.</description>
          <population>Intent-to-treat population</population>
          <units>cumulative percent of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60"/>
                    <measurement group_id="O2" value="0.83"/>
                    <measurement group_id="O3" value="1.49"/>
                    <measurement group_id="O4" value="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20"/>
                    <measurement group_id="O2" value="21.73"/>
                    <measurement group_id="O3" value="32.93"/>
                    <measurement group_id="O4" value="27.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.83"/>
                    <measurement group_id="O2" value="39.43"/>
                    <measurement group_id="O3" value="51.22"/>
                    <measurement group_id="O4" value="48.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.22"/>
                    <measurement group_id="O2" value="52.40"/>
                    <measurement group_id="O3" value="57.32"/>
                    <measurement group_id="O4" value="62.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.68"/>
                    <measurement group_id="O2" value="65.99"/>
                    <measurement group_id="O3" value="66.47"/>
                    <measurement group_id="O4" value="65.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.57"/>
                    <measurement group_id="O2" value="69.79"/>
                    <measurement group_id="O3" value="69.66"/>
                    <measurement group_id="O4" value="71.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.59"/>
                    <measurement group_id="O2" value="74.11"/>
                    <measurement group_id="O3" value="74.66"/>
                    <measurement group_id="O4" value="73.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.62"/>
                    <measurement group_id="O2" value="76.27"/>
                    <measurement group_id="O3" value="76.47"/>
                    <measurement group_id="O4" value="73.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 9 to 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.30"/>
                    <measurement group_id="O2" value="82.20"/>
                    <measurement group_id="O3" value="83.82"/>
                    <measurement group_id="O4" value="76.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis refers to the test of the null hypothesis that there is no difference in the survival distribution function between the treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1143</p_value>
            <method>Generalized Wilcoxon</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis refers to the test of the null hypothesis that there is no difference in the survival distribution function between the treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4544</p_value>
            <method>Generalized Wilcoxon</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total HAM-A Score After 1 Week</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
        <time_frame>Baseline and 1 week</time_frame>
        <population>ITT population, but only subjects with values at baseline and time point are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total HAM-A Score After 1 Week</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
          <population>ITT population, but only subjects with values at baseline and time point are included in the analysis</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.3" spread="11.50"/>
                    <measurement group_id="O2" value="-5.8" spread="9.04"/>
                    <measurement group_id="O3" value="-7.8" spread="7.43"/>
                    <measurement group_id="O4" value="-4.6" spread="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANCOVA with treatment as a fixed effect and baseline total HAM-A score as a covariate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0173</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANCOVA with treatment as a fixed effect and baseline total HAM-A score as a covariate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0516</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total HAM-A Score After 2 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
        <time_frame>Baseline and 2 Weeks</time_frame>
        <population>ITT Population, only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total HAM-A Score After 2 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
          <population>ITT Population, only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.6" spread="10.98"/>
                    <measurement group_id="O2" value="-8.2" spread="9.37"/>
                    <measurement group_id="O3" value="-10.0" spread="8.75"/>
                    <measurement group_id="O4" value="-6.1" spread="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0361</p_value>
            <p_value_desc>P-value based on ANCOVA model with treatment as a fixed effect and baseline total HAM-A score as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0366</p_value>
            <p_value_desc>P-value based on ANCOVA model with treatment as a fixed effect and baseline total HAM-A score as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total HAM-A Score After 3 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
        <time_frame>Baseline and 3 weeks</time_frame>
        <population>ITT population, only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total HAM-A Score After 3 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
          <population>ITT population, only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.3" spread="11.81"/>
                    <measurement group_id="O2" value="-12.9" spread="11.03"/>
                    <measurement group_id="O3" value="-10.9" spread="9.70"/>
                    <measurement group_id="O4" value="-9.5" spread="9.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7390</p_value>
            <p_value_desc>P-value based on ANCOVA model with treatment as a fixed effect and baseline total HAM-A score as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6735</p_value>
            <p_value_desc>P-value based on ANCOVA model with treatment as a fixed effect and baseline total HAM-A score as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total HAM-A Score After 4 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>ITT population, only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total HAM-A Score After 4 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
          <population>ITT population, only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.2" spread="11.66"/>
                    <measurement group_id="O2" value="-13.7" spread="10.58"/>
                    <measurement group_id="O3" value="-12.9" spread="9.47"/>
                    <measurement group_id="O4" value="-8.3" spread="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4261</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline total HAM-A score as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0231</p_value>
            <p_value_desc>P-value based on ANCOVA with treatment as a fixed effect and baseline HAM-A score as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total HAM-A Score After 5 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
        <time_frame>Baseline and 5 weeks</time_frame>
        <population>ITT population, only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total HAM-A Score After 5 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
          <population>ITT population, only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.7" spread="11.81"/>
                    <measurement group_id="O2" value="-14.4" spread="11.69"/>
                    <measurement group_id="O3" value="-13.3" spread="8.41"/>
                    <measurement group_id="O4" value="-10.3" spread="10.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1820</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and total HAM-A score as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2187</p_value>
            <p_value_desc>P-value based on ANCOVA model with treatment as a fixed effect and baseline total HAM-A score as covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total HAM-A Score After 6 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>ITT population, only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total HAM-A Score After 6 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
          <population>ITT population, only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.7" spread="11.94"/>
                    <measurement group_id="O2" value="-15.1" spread="11.59"/>
                    <measurement group_id="O3" value="-13.4" spread="8.00"/>
                    <measurement group_id="O4" value="-11.0" spread="10.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1456</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline total HAM-A score as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3618</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline total HAM-A score as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total HAM-A Score After 7 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
        <time_frame>Baseline and 7 weeks</time_frame>
        <population>ITT population, only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total HAM-A Score After 7 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
          <population>ITT population, only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.7" spread="12.75"/>
                    <measurement group_id="O2" value="-15.6" spread="11.78"/>
                    <measurement group_id="O3" value="-13.3" spread="8.85"/>
                    <measurement group_id="O4" value="-11.3" spread="11.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3535</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline total HAM-A score as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5660</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline total HAM-A score as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total HAM-A Score After 8 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>ITT population, only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total HAM-A Score After 8 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56.</description>
          <population>ITT population, only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.5" spread="13.38"/>
                    <measurement group_id="O2" value="-16.6" spread="10.72"/>
                    <measurement group_id="O3" value="-13.9" spread="8.71"/>
                    <measurement group_id="O4" value="-12.3" spread="9.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3414</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline total HAM-A score as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7344</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline total HAM-A score as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total HAM-A Score at Endpoint During the 8 Week Treatment Period</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56. Endpoint is last observed value during the 8 week treatment period.</description>
        <time_frame>Baseline and at endpoint during the 8 week treatment period</time_frame>
        <population>ITT population, Last Observation Carried Forward imputation was applied</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total HAM-A Score at Endpoint During the 8 Week Treatment Period</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum HAM-A Score is 56. Endpoint is last observed value during the 8 week treatment period.</description>
          <population>ITT population, Last Observation Carried Forward imputation was applied</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.3" spread="13.03"/>
                    <measurement group_id="O2" value="-14.3" spread="11.32"/>
                    <measurement group_id="O3" value="-13.6" spread="8.85"/>
                    <measurement group_id="O4" value="-11.5" spread="10.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1197</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline total HAM-A score as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4416</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline total HAM-A score as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 1 Week</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
        <time_frame>1 week</time_frame>
        <population>ITT population, but only patients with a non-missing value at timepoint are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 1 Week</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
          <population>ITT population, but only patients with a non-missing value at timepoint are included in the analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis refers to test of differences in response rates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0350</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis refers to test of differences in response rates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4205</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 2 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
        <time_frame>2 weeks</time_frame>
        <population>ITT population, but only patients with a non-missing value at timepoint are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 2 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
          <population>ITT population, but only patients with a non-missing value at timepoint are included in the analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis refers to test of differences in response rates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2645</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis refers to test of differences in response rates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5369</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 3 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
        <time_frame>3 weeks</time_frame>
        <population>ITT population, but only patients with a non-missing value at timepoint are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 3 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
          <population>ITT population, but only patients with a non-missing value at timepoint are included in the analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis refers to test of differences in response rates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9988</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis refers to test of differences in response rates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7729</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 4 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
        <time_frame>4 weeks</time_frame>
        <population>ITT population, but only patients with a non-missing value at timepoint are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 4 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
          <population>ITT population, but only patients with a non-missing value at timepoint are included in the analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis refers to test of differences in response rates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7338</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis refers to test of differences in response rates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0897</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 5 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
        <time_frame>5 weeks</time_frame>
        <population>ITT population, but only patients with a non-missing value at timepoint are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 5 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
          <population>ITT population, but only patients with a non-missing value at timepoint are included in the analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis refers to test of differences in response rates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6501</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis refers to test of differences in response rates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8196</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 6 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
        <time_frame>6 weeks</time_frame>
        <population>ITT population, but only patients with a non-missing value at timepoint are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 6 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
          <population>ITT population, but only patients with a non-missing value at timepoint are included in the analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis refers to test of differences in response rates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6404</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis refers to test of differences in response rates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8263</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 7 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
        <time_frame>7 weeks</time_frame>
        <population>ITT population, but only patients with a non-missing value at timepoint are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 7 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
          <population>ITT population, but only patients with a non-missing value at timepoint are included in the analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis refers to test of differences in response rates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6946</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis refers to test of differences in response rates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9629</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 8 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
        <time_frame>8 weeks</time_frame>
        <population>ITT population, but only patients with a non-missing value at timepoint are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) After 8 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).</description>
          <population>ITT population, but only patients with a non-missing value at timepoint are included in the analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis refers to test of differences in response rates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8617</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis refers to test of differences in response rates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7555</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) at Endpoint During the 8 Week Treatment Period</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Endpoint is last observed value during the 8 week treatment period.</description>
        <time_frame>at endpoint during the 8 week treatment period</time_frame>
        <population>ITT population, Last Observation Carried Forward imputation was applied</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response (Decrease From Baseline in Total HAM-A-score &gt;=50%) at Endpoint During the 8 Week Treatment Period</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Endpoint is last observed value during the 8 week treatment period.</description>
          <population>ITT population, Last Observation Carried Forward imputation was applied</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis refers to test of differences in response rates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5836</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis refers to test of differences in response rates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9096</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Severity of Illness From Baseline Using the Clinical Global Impression Improvement (CGI-I) Score After 2 Weeks</title>
        <description>The Clinical Global Impression Improvement (CGI-I) scale is a 7 point ordinal scale that assesses how the patient's illness has improved ranging from 'very much improved' to 'very much worse'(see definition of categories in results table).</description>
        <time_frame>Baseline and 2 weeks</time_frame>
        <population>ITT population, but only patients with non-missing values were included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Severity of Illness From Baseline Using the Clinical Global Impression Improvement (CGI-I) Score After 2 Weeks</title>
          <description>The Clinical Global Impression Improvement (CGI-I) scale is a 7 point ordinal scale that assesses how the patient's illness has improved ranging from 'very much improved' to 'very much worse'(see definition of categories in results table).</description>
          <population>ITT population, but only patients with non-missing values were included</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Severity of Illness From Baseline Using the Clinical Global Impression - Improvement (CGI-I) Score After 4 Weeks</title>
        <description>The Clinical Global Impression Improvement (CGI-I) scale is a 7 point ordinal scale that assesses how the patient's illness has improved ranging from 'very much improved' to 'very much worse'(see definition of categories in results table).</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Severity of Illness From Baseline Using the Clinical Global Impression - Improvement (CGI-I) Score After 4 Weeks</title>
          <description>The Clinical Global Impression Improvement (CGI-I) scale is a 7 point ordinal scale that assesses how the patient's illness has improved ranging from 'very much improved' to 'very much worse'(see definition of categories in results table).</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint, CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0255</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0065</p_value>
            <method>van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Severity of Illness From Baseline Using the Clinical Global Impression - Improvement (CGI-I) Score After 8 Weeks</title>
        <description>The Clinical Global Impression Improvement (CGI-I) scale is a 7 point ordinal scale that assesses how the patient's illness has improved ranging from 'very much improved' to 'very much worse'(see definition of categories in results table).</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Severity of Illness From Baseline Using the Clinical Global Impression - Improvement (CGI-I) Score After 8 Weeks</title>
          <description>The Clinical Global Impression Improvement (CGI-I) scale is a 7 point ordinal scale that assesses how the patient's illness has improved ranging from 'very much improved' to 'very much worse'(see definition of categories in results table).</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0370</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9569</p_value>
            <method>van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Severity of Illness From Baseline Using the Clinical Global Impression - Improvement (CGI-I) Score at Endpoint During the 8 Week Treatment Period</title>
        <description>The Clinical Global Impression Improvement (CGI-I) scale is a 7 point ordinal scale that assesses how the patient's illness has improved ranging from 'very much improved' to 'very much worse'(see definition of categories in results table). Endpoint is last observed value during the 8 week treatment period.</description>
        <time_frame>Baseline and at endpoint during the 8 week treatment period</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Severity of Illness From Baseline Using the Clinical Global Impression - Improvement (CGI-I) Score at Endpoint During the 8 Week Treatment Period</title>
          <description>The Clinical Global Impression Improvement (CGI-I) scale is a 7 point ordinal scale that assesses how the patient's illness has improved ranging from 'very much improved' to 'very much worse'(see definition of categories in results table). Endpoint is last observed value during the 8 week treatment period.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0978</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7096</p_value>
            <method>van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 1 Week</title>
        <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
        <time_frame>1 week</time_frame>
        <population>ITT population, but only patients with non-missing values are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 1 Week</title>
          <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
          <population>ITT population, but only patients with non-missing values are included in the analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 2 Weeks</title>
        <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect.</description>
        <time_frame>2 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 2 Weeks</title>
          <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0025</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0101</p_value>
            <method>van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 3 Weeks</title>
        <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
        <time_frame>3 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 3 Weeks</title>
          <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0095</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0390</p_value>
            <method>van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 4 Weeks</title>
        <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
        <time_frame>4 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 4 Weeks</title>
          <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0160</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1024</p_value>
            <method>van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 5 Weeks</title>
        <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
        <time_frame>5 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 5 Weeks</title>
          <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0761</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0376</p_value>
            <method>van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 6 Weeks</title>
        <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
        <time_frame>6 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 6 Weeks</title>
          <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1196</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint.CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0029</p_value>
            <method>van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 7 Weeks</title>
        <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
        <time_frame>7 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 7 Weeks</title>
          <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6323</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5533</p_value>
            <method>van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 8 Weeks</title>
        <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
        <time_frame>8 weeks</time_frame>
        <population>ITT population, Last Observation Carried Forward imputation was applied</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 8 Weeks</title>
          <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables).</description>
          <population>ITT population, Last Observation Carried Forward imputation was applied</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1705</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3196</p_value>
            <method>van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score at Endpoint During the 8 Week Treatment Period</title>
        <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables). Endpoint is last observed value during the 8 week treatment period.</description>
        <time_frame>at endpoint during the 8 week treatment period</time_frame>
        <population>ITT population, Last Observation Carried Forward imputation was applied</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score at Endpoint During the 8 Week Treatment Period</title>
          <description>The Patient Global Impression (PGI) scale is a 7 point ordinal scale that rates subject's assessment of treatment effect ranging from 'very much better' to 'very much worse' (see categories in results tables). Endpoint is last observed value during the 8 week treatment period.</description>
          <population>ITT population, Last Observation Carried Forward imputation was applied</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0419</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>van Elteren test stratified by CGI-Severity score at baseline and testing between treatment differences in percentages based on non-missing responses within a timepoint. CGI-Severity score categorizes severity at baseline as normal,not at all ill, borderline mentally ill, mildly ill, moderately ill, markedly ill, severely ill, among the most extremely ill.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2541</p_value>
            <method>van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-insomnia Subscore After 1 Week</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
        <time_frame>Baseline and 1 week</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-insomnia Subscore After 1 Week</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.42"/>
                    <measurement group_id="O2" value="-0.6" spread="1.43"/>
                    <measurement group_id="O3" value="-1.0" spread="1.40"/>
                    <measurement group_id="O4" value="-0.5" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0677</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAM-A insomnia subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0273</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAM-A insomnia subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-insomnia Subscore After 2 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
        <time_frame>Baseline and 2 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-insomnia Subscore After 2 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.49"/>
                    <measurement group_id="O2" value="-0.9" spread="1.40"/>
                    <measurement group_id="O3" value="-1.2" spread="1.50"/>
                    <measurement group_id="O4" value="-0.6" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5153</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAM-A insomnia subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0122</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAM-A insomnia subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-insomnia Subscore After 3 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
        <time_frame>Baseline and 3 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-insomnia Subscore After 3 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.48"/>
                    <measurement group_id="O2" value="-1.1" spread="1.43"/>
                    <measurement group_id="O3" value="-1.4" spread="1.40"/>
                    <measurement group_id="O4" value="-1.2" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4648</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAM-A insomnia subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5502</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAM-A insomnia subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-insomnia Subscore After 4 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-insomnia Subscore After 4 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="1.65"/>
                    <measurement group_id="O2" value="-1.4" spread="1.47"/>
                    <measurement group_id="O3" value="-1.6" spread="1.34"/>
                    <measurement group_id="O4" value="-1.1" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9093</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAM-A insomnia subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1354</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAM-A insomnia subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-insomnia Subscore After 5 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
        <time_frame>Baseline and 5 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-insomnia Subscore After 5 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="1.56"/>
                    <measurement group_id="O2" value="-1.4" spread="1.52"/>
                    <measurement group_id="O3" value="-1.5" spread="1.36"/>
                    <measurement group_id="O4" value="-1.1" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7434</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAM-A insomnia subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1148</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAM-A insomnia subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-insomnia Subscore After 6 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-insomnia Subscore After 6 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="1.64"/>
                    <measurement group_id="O2" value="-1.5" spread="1.52"/>
                    <measurement group_id="O3" value="-1.6" spread="1.25"/>
                    <measurement group_id="O4" value="-1.1" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9346</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A insomnia subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2709</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAM-A insomnia subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-insomnia Subscore After 7 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
        <time_frame>Baseline and 7 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-insomnia Subscore After 7 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="1.63"/>
                    <measurement group_id="O2" value="-1.4" spread="1.49"/>
                    <measurement group_id="O3" value="-1.6" spread="1.32"/>
                    <measurement group_id="O4" value="-1.2" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3827</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAM-A insomnia subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2513</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAM-A insomnia subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-insomnia Subscore After 8 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-insomnia Subscore After 8 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="1.57"/>
                    <measurement group_id="O2" value="-1.6" spread="1.41"/>
                    <measurement group_id="O3" value="-1.6" spread="1.33"/>
                    <measurement group_id="O4" value="-1.3" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3930</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAM-A insomnia subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5461</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAM-A insomnia subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-insomnia Subscore at Endpoint During the 8 Week Treatment Period</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4. Endpoint is last observed value during the 8 week treatment period.</description>
        <time_frame>Baseline and at endpoint during the 8 week treatment period</time_frame>
        <population>ITT population, Last Observation Carried Forward imputation was applied</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-insomnia Subscore at Endpoint During the 8 Week Treatment Period</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the insomnia subscore is 4. Endpoint is last observed value during the 8 week treatment period.</description>
          <population>ITT population, Last Observation Carried Forward imputation was applied</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="1.53"/>
                    <measurement group_id="O2" value="-1.4" spread="1.49"/>
                    <measurement group_id="O3" value="-1.5" spread="1.38"/>
                    <measurement group_id="O4" value="-1.3" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0722</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAM-A insomnia subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4639</p_value>
            <p_value_desc>P-values based on an ANCOVA with treatment as a fixed effect and baseline HAM-A insomnia subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-psychic Factors Subscore After 1 Week</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
        <time_frame>Baseline and 1 week</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-psychic Factors Subscore After 1 Week</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="5.73"/>
                    <measurement group_id="O2" value="-2.9" spread="4.78"/>
                    <measurement group_id="O3" value="-4.5" spread="4.53"/>
                    <measurement group_id="O4" value="-3.3" spread="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0075</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A psychic factors subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1641</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAM-A psychic factors subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-psychic Factors Subscore After 2 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
        <time_frame>Baseline and 2 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-psychic Factors Subscore After 2 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="5.97"/>
                    <measurement group_id="O2" value="-4.5" spread="4.88"/>
                    <measurement group_id="O3" value="-5.8" spread="5.23"/>
                    <measurement group_id="O4" value="-4.1" spread="4.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0932</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A psychic factors subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0852</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A psychic factors subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-psychic Factors Subscore After 3 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
        <time_frame>Baseline and 3 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-psychic Factors Subscore After 3 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="5.98"/>
                    <measurement group_id="O2" value="-6.8" spread="5.42"/>
                    <measurement group_id="O3" value="-6.4" spread="5.44"/>
                    <measurement group_id="O4" value="-6.1" spread="4.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7896</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A psychic factors subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9651</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A psychic factors subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-psychic Factors Subscore After 4 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-psychic Factors Subscore After 4 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="5.95"/>
                    <measurement group_id="O2" value="-7.4" spread="5.57"/>
                    <measurement group_id="O3" value="-7.8" spread="5.14"/>
                    <measurement group_id="O4" value="-5.9" spread="4.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8280</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A psychic factors subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0936</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A psychic factors subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-psychic Factors Subscore After 5 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
        <time_frame>Baseline and 5 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-psychic Factors Subscore After 5 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="5.84"/>
                    <measurement group_id="O2" value="-7.7" spread="5.99"/>
                    <measurement group_id="O3" value="-7.9" spread="5.08"/>
                    <measurement group_id="O4" value="-6.8" spread="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3539</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A psychic factors subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4672</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A psychic factors subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-psychic Factors Subscore After 6 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-psychic Factors Subscore After 6 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="5.84"/>
                    <measurement group_id="O2" value="-8.3" spread="5.66"/>
                    <measurement group_id="O3" value="-8.7" spread="4.81"/>
                    <measurement group_id="O4" value="-7.2" spread="5.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2550</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A psychic factors subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3125</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A psychic factors subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-psychic Factors Subscore After 7 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
        <time_frame>Baseline and 7 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-psychic Factors Subscore After 7 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="6.27"/>
                    <measurement group_id="O2" value="-8.4" spread="5.75"/>
                    <measurement group_id="O3" value="-8.1" spread="5.16"/>
                    <measurement group_id="O4" value="-7.6" spread="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3174</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A psychic factors subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9427</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A psychic factors subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-psychic Factors Subscore After 8 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-psychic Factors Subscore After 8 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.9" spread="6.63"/>
                    <measurement group_id="O2" value="-8.9" spread="5.13"/>
                    <measurement group_id="O3" value="-8.5" spread="4.91"/>
                    <measurement group_id="O4" value="-8.5" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3252</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A psychic factors subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6090</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A psychic factors subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-psychic Factors Subscore at Endpoint During the 8 Week Treatment Period</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4. Endpoint is last observed value during the 8 week treatment period.</description>
        <time_frame>Baseline and at endpoint during the 8 week treatment period</time_frame>
        <population>ITT population, Last Observation Carried Forward imputation was applied</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-psychic Factors Subscore at Endpoint During the 8 Week Treatment Period</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the psychic factors subscore is 4. Endpoint is last observed value during the 8 week treatment period.</description>
          <population>ITT population, Last Observation Carried Forward imputation was applied</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.1" spread="6.58"/>
                    <measurement group_id="O2" value="-7.6" spread="5.82"/>
                    <measurement group_id="O3" value="-7.9" spread="5.19"/>
                    <measurement group_id="O4" value="-7.9" spread="5.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1247</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A psychic factors subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8430</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A psychic factors subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-somatic Subscore After 1 Week</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
        <time_frame>Baseline and 1 week</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-somatic Subscore After 1 Week</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="6.95"/>
                    <measurement group_id="O2" value="-2.9" spread="5.80"/>
                    <measurement group_id="O3" value="-3.3" spread="4.46"/>
                    <measurement group_id="O4" value="-1.4" spread="5.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1031</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A somatic subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0543</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A somatic subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-somatic Subscore After 2 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
        <time_frame>Baseline and 2 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-somatic Subscore After 2 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="6.31"/>
                    <measurement group_id="O2" value="-3.7" spread="6.18"/>
                    <measurement group_id="O3" value="-4.2" spread="5.52"/>
                    <measurement group_id="O4" value="-2.0" spread="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0508</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A somatic subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0871</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A somatic subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-somatic Subscore After 3 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
        <time_frame>Baseline and 3 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-somatic Subscore After 3 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="7.03"/>
                    <measurement group_id="O2" value="-6.1" spread="7.55"/>
                    <measurement group_id="O3" value="-4.5" spread="5.85"/>
                    <measurement group_id="O4" value="-3.4" spread="6.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8318</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A somatic subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5375</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A somatic subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-somatic Subscore After 4 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-somatic Subscore After 4 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="6.96"/>
                    <measurement group_id="O2" value="-6.4" spread="6.50"/>
                    <measurement group_id="O3" value="-5.1" spread="5.95"/>
                    <measurement group_id="O4" value="-2.3" spread="5.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2186</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A somatic subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0422</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A somatic subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-somatic Subscore After 5 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
        <time_frame>Baseline and 5 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-somatic Subscore After 5 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="7.21"/>
                    <measurement group_id="O2" value="-6.8" spread="7.14"/>
                    <measurement group_id="O3" value="-5.4" spread="5.31"/>
                    <measurement group_id="O4" value="-3.4" spread="6.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1164</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A somatic subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1935</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A somatic subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-somatic Subscore After 6 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-somatic Subscore After 6 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="7.41"/>
                    <measurement group_id="O2" value="-6.8" spread="7.32"/>
                    <measurement group_id="O3" value="-4.7" spread="4.83"/>
                    <measurement group_id="O4" value="-3.8" spread="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1244</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A somatic subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6182</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A somatic subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-somatic Subscore After 7 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
        <time_frame>Baseline and 7 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-somatic Subscore After 7 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="7.74"/>
                    <measurement group_id="O2" value="7.2" spread="7.38"/>
                    <measurement group_id="O3" value="-5.2" spread="5.37"/>
                    <measurement group_id="O4" value="-3.7" spread="6.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4589</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A somatic subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3930</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A somatic subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-somatic Subscore After 8 Weeks</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-somatic Subscore After 8 Weeks</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4.</description>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="7.98"/>
                    <measurement group_id="O2" value="-7.7" spread="7.43"/>
                    <measurement group_id="O3" value="-5.5" spread="5.53"/>
                    <measurement group_id="O4" value="-3.8" spread="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4450</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A somatic subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2924</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A somatic subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A-somatic Subscore at Endpoint During the 8 Week Treatment Period</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4. Endpoint is last observed value during the 8 week treatment period.</description>
        <time_frame>Baseline and at endpoint during the 8 week treatment period</time_frame>
        <population>ITT population, Last Observation Carried Forward imputation was applied</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A-somatic Subscore at Endpoint During the 8 Week Treatment Period</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Maximum score of the somatic subscore is 4. Endpoint is last observed value during the 8 week treatment period.</description>
          <population>ITT population, Last Observation Carried Forward imputation was applied</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="7.86"/>
                    <measurement group_id="O2" value="-6.7" spread="7.18"/>
                    <measurement group_id="O3" value="-5.6" spread="5.72"/>
                    <measurement group_id="O4" value="-3.6" spread="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2184</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A somatic subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1281</p_value>
            <p_value_desc>P-value based on an ANCOVA model with treatment as a fixed effect and baseline HAMA-A psychic factors subscore as a covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 1 Week</title>
        <time_frame>1 week</time_frame>
        <population>ITT population, but only patients with non-missing assessments were included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 1 Week</title>
          <population>ITT population, but only patients with non-missing assessments were included</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any panic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No panic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>test of difference in percentage of subjects reporting any panic attack</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6602</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 2 Weeks</title>
        <time_frame>2 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 2 Weeks</title>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any panic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No panic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>test of difference in percentage of subjects reporting any panic attack</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5544</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 3 Weeks</title>
        <time_frame>3 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 3 Weeks</title>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any panic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No panic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>test of difference in percentage of subjects reporting any panic attack</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9269</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 4 Weeks</title>
        <time_frame>4 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 4 Weeks</title>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any panic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No panic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>test of difference in percentage of subjects reporting any panic attack</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5271</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 5 Weeks</title>
        <time_frame>5 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 5 Weeks</title>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any panic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No panic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>test of difference in percentage of subjects reporting any panic attack</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1447</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 6 Weeks</title>
        <time_frame>6 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 6 Weeks</title>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any panic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No panic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9375</p_value>
            <p_value_desc>P-value from a Chi-squared test</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 7 Weeks</title>
        <time_frame>7 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 7 Weeks</title>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any panic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No panic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>test of difference in percentage of subjects reporting any panic attack</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9883</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 8 Weeks</title>
        <time_frame>8 weeks</time_frame>
        <population>ITT population, but only subjects with non-missing values have been included</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 8 Weeks</title>
          <population>ITT population, but only subjects with non-missing values have been included</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any panic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No panic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>test of difference in percentage of subjects reporting any panic attack</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3093</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) at Endpoint During the 8 Week Treatment Period</title>
        <description>Endpoint is last observed value during the 8 week treatment period.</description>
        <time_frame>at endpoint during the 8 week treatment period</time_frame>
        <population>ITT population, Last Observation Carried Forward imputation was applied</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) at Endpoint During the 8 Week Treatment Period</title>
          <description>Endpoint is last observed value during the 8 week treatment period.</description>
          <population>ITT population, Last Observation Carried Forward imputation was applied</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any panic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No panic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>test of difference in percentage of subjects reporting any panic attack</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5824</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Percent of Participants Showing a Response in the Symptoms of Anxiety (Decrease in Total Hamilton Anxiety (HAM-A) -Score of &gt;=50%) in the Per Protocol Population (Kaplan-Meier-estimates)</title>
        <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Total possible score is 56. Kaplan-Meier-analysis was performed and Kaplan-Meier estimates (cumulative percent of subjects responding) are presented.</description>
        <time_frame>10 weeks</time_frame>
        <population>Per Protocol Population (subjects of ITT population who have no major protocol violations)</population>
        <group_list>
          <group group_id="O1">
            <title>Panic: Niravam+SSRI/SNRI</title>
            <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O2">
            <title>Panic: SSRI/SNRI Alone</title>
            <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
          <group group_id="O3">
            <title>GAD : Niravam+SSRI/SNRI</title>
            <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
          </group>
          <group group_id="O4">
            <title>GAD: SSRI/SNRI Alone</title>
            <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Percent of Participants Showing a Response in the Symptoms of Anxiety (Decrease in Total Hamilton Anxiety (HAM-A) -Score of &gt;=50%) in the Per Protocol Population (Kaplan-Meier-estimates)</title>
          <description>The Hamilton Anxiety (HAM-A) Rating scale is a test of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe). Total possible score is 56. Kaplan-Meier-analysis was performed and Kaplan-Meier estimates (cumulative percent of subjects responding) are presented.</description>
          <population>Per Protocol Population (subjects of ITT population who have no major protocol violations)</population>
          <units>cumulative percent of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92"/>
                    <measurement group_id="O2" value="0.94"/>
                    <measurement group_id="O3" value="1.89"/>
                    <measurement group_id="O4" value="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.58"/>
                    <measurement group_id="O2" value="24.53"/>
                    <measurement group_id="O3" value="33.96"/>
                    <measurement group_id="O4" value="30.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.23"/>
                    <measurement group_id="O2" value="41.54"/>
                    <measurement group_id="O3" value="52.83"/>
                    <measurement group_id="O4" value="53.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.18"/>
                    <measurement group_id="O2" value="54.19"/>
                    <measurement group_id="O3" value="58.49"/>
                    <measurement group_id="O4" value="67.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.45"/>
                    <measurement group_id="O2" value="67.59"/>
                    <measurement group_id="O3" value="67.92"/>
                    <measurement group_id="O4" value="71.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.59"/>
                    <measurement group_id="O2" value="71.94"/>
                    <measurement group_id="O3" value="71.70"/>
                    <measurement group_id="O4" value="79.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.83"/>
                    <measurement group_id="O2" value="75.77"/>
                    <measurement group_id="O3" value="77.70"/>
                    <measurement group_id="O4" value="79.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.95"/>
                    <measurement group_id="O2" value="78.32"/>
                    <measurement group_id="O3" value="79.93"/>
                    <measurement group_id="O4" value="79.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 to 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.60"/>
                    <measurement group_id="O2" value="84.82"/>
                    <measurement group_id="O3" value="86.62"/>
                    <measurement group_id="O4" value="82.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis refers to the test of the null hypothesis that there is no difference in the survival distribution function between the treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <method>Generalized Wilcoxon Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis refers to the test of the null hypothesis that there is no difference in the survival distribution function between the treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6587</p_value>
            <method>Generalized Wilcoxon Test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The safety population consists of 414 subjects that received at least one dose of SSRI/SNRI and/or Niravam.</desc>
      <group_list>
        <group group_id="E1">
          <title>Panic: Niravam+SSRI/SNRI</title>
          <description>Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI</description>
        </group>
        <group group_id="E2">
          <title>Panic: SSRI/SNRI Alone</title>
          <description>Panic Disorder: Newly prescribed SSRI or SNRI alone</description>
        </group>
        <group group_id="E3">
          <title>GAD : Niravam+SSRI/SNRI</title>
          <description>Generalized Anxiety Disorder: Niravam plus newly prescribed SSRI or SNRI</description>
        </group>
        <group group_id="E4">
          <title>GAD: SSRI/SNRI Alone</title>
          <description>Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 8.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Postoperative infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Sternitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Multiple drug overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Bacterial Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Temporal Arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 8.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>UCB has &gt; 60 days but &lt;= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Originally it was planned to enrol and randomize 848 subjects. The smaller than planned sample size was a result of an unusually high rate of screening failure (results published in Psychiatry 2006, Vol. 3, Issue 12 , pages 39 - 59).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>UCB Clinical Trial Call Center</name_or_title>
      <organization>UCB Pharma</organization>
      <phone>+1 877 822 9493</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

